FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:189-192 January 8, 2004 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Khosla, S. Related Article by Black, D. M. Related Article by Finkelstein, J. S. PubMed Citation

To the Editor: Both Black et al.¹ and Finkelstein et al.² (Sept. 25 issue) measured markers of bone turnover, but neither group took osteoprotegerin into consideration as a possibly relevant player in bone remodeling. Osteoprotegerin, a secreted member of the family of tumor necrosis factor receptors, is a potent inhibitor of osteoclast activation and differentiation.^3,4 In patients with osteoporosis, osteoprotegerin has been found to correlate strongly with markers of bone turnover⁵ — a finding that may point toward a higher level of osteoprotegerin expression in patients with a higher level of these markers.

In limited experimental settings, the serum osteoprotegerin . . . [Full Text of this Article]

This article has been cited by other articles:

• Kondo, H., Nifuji, A., Takeda, S., Ezura, Y., Rittling, S. R., Denhardt, D. T., Nakashima, K., Karsenty, G., Noda, M. (2005). Unloading Induces Osteoblastic Cell Suppression and Osteoclastic Cell Activation to Lead to Bone Loss via Sympathetic Nervous System. J. Biol. Chem. 280: 30192-30200 [Abstract] [Full Text]